探索深静脉血栓形成表型与复发以外临床结局的关系
研究对825例深静脉血栓患者基于23项基线特征进行层次聚类,随访至5年,识别出4种表型,并分析其与复发静脉血栓栓塞、血栓后综合征、动脉事件及癌症的关联。结果显示各表型风险不同,雌激素治疗女性风险最低,心血管风险特征患者风险最高。
要点
- 共识别4种深静脉血栓表型:雌激素治疗女性112例、心血管风险特征268例、既往静脉血栓栓塞128例、无判别特征317例。
- 以表型1为参照,表型4的复发、血栓后综合征、动脉事件、癌症风险比分别为4.6、1.2、2.2、1.8。
- 表型2和表型3的上述风险比分别为6.1、1.6、4.5、2.9和5.7、2.5、2.3、3.7。
核心结论
- 研究识别出4种深静脉血栓表型,不仅与递增的复发风险相关,也与复发以外的结局相关。
- 结果突显了仅基于复发风险预测因素进行风险分层的现行分层方法的局限性。
- 总体风险在雌激素治疗女性中最低,在心血管风险特征患者中最高。
- 这些发现可能有助于更个体化的临床管理。
研究设计与样本
- 对深静脉血栓队列进行层次聚类分析,使用23项基线特征,随访至5年。
- 采用Cox回归计算风险比,复发风险根据抗凝治疗时长进行调整。
- 研究遵循赫尔辛基宣言并获得医学伦理委员会批准。
主要发现
- 825例患者被聚类为4种表型:1. 使用雌激素治疗的女性(n=112);2. 具有心血管风险特征的患者(n=268);3. 既往静脉血栓栓塞患者(n=128);4. 无判别特征的患者(n=317)。
- 以表型1为参照,表型4的复发、血栓后综合征、动脉事件、癌症风险比分别为4.6、1.2、2.2、1.8。
- 表型2的复发、血栓后综合征、动脉事件、癌症风险比分别为6.1、1.6、4.5、2.9。
- 表型3的复发、血栓后综合征、动脉事件、癌症风险比分别为5.7、2.5、2.3、3.7。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deep vein thrombosis (DVT) is a multifactorial disease with several outcomes, but current classifications solely stratify it based on recurrence risk. OBJECTIVES: We aimed to identify DVT phenotypes and assess their relation to recurrent venous thromboembolism (VTE), postthrombotic syndrome, arterial events, and cancer. PATIENTS/METHODS: Hierarchical clustering was performed on a DVT cohort with a follow-up of up to 5 years using 23 baseline characteristics. Phenotypes were summarized by discriminative characteristics. Hazard ratios (HRs) were calculated using Cox regression; the recurrence risk was adjusted for the anticoagulant therapy duration. The study was carried out in accordance with the Declaration of Helsinki and approved by the medical ethics committee. RESULTS: In total, 825 patients were clustered into 4 phenotypes: 1. women using estrogen therapy (n = 112); 2. patients with a cardiovascular risk profile (n = 268); 3. patients with previous VTE (n = 128); and 4. patients without discriminant characteristics (n = 317). Overall, the risks of recurrence, postthrombotic syndrome, arterial events, and cancer were low in phenotype 1 (reference), intermediate in phenotype 4 (HR: 4.6, 1.2, 2.2, 1.8), and high in phenotypes 2 (HR: 6.1, 1.6, 4.5, 2.9) and 3 (HR: 5.7, 2.5, 2.3, 3.7). CONCLUSIONS: This study identified 4 distinct phenotypes among patients with DVT that are not only associated with the increasing recurrence risk but also with outcomes beyond recurrence. Our results thereby highlight the limitations of current risk stratifications that stratify based on the predictors of the recurrence risk only. Overall, risks were lowest in women using estrogen therapy and highest in patients with a cardiovascular risk profile. These findings might inform a more personalized approach to clinical management.
引用
- Iding AFJ, Pallares Robles A, Ten Cate V, et al. Exploring phenotypes of deep vein thrombosis in relation to clinical outcomes beyond recurrence. J Thromb Haemost. 2023. PMID: 36736833. doi:10.1016/j.jtha.2023.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。